Peptide
GHK-Cu
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex)
A copper-binding tripeptide that falls with age. Solid topical dermatology evidence for wound healing and skin repair. Systemic longevity claims remain speculative.
Summary Does GHK-Cu really repair skin or slow aging? Show / hide ↓
GHK-Cu is a small chain of amino acids that binds copper, used mainly in skin creams. Several placebo-controlled trials, which compare it with inactive creams, found that creams around 3% improved wound healing, fine lines, skin thickness, and elasticity. It may help skin cells make collagen, a protein that supports skin strength, and other materials needed for repair. Claims that injections slow whole-body aging are based only on cell studies and biological theories; no completed human randomized controlled trial, where people are assigned treatments by chance, has tested this. Injectable use also adds copper, which may be risky for people with copper-processing problems.
What this means for you: Topical GHK-Cu has useful evidence for skin repair and some signs of improved skin aging. Injectable GHK-Cu for longer life or whole-body rejuvenation is not supported by good human studies, so it is not enough evidence to buy it for those purposes.
moderate evidenceGHK-Cu is one of the older peptides in the longevity conversation, and one of the most solidly supported for its narrow indication: topical skin repair. The peptide was first described by Loren Pickart in 1973 as a growth-promoting factor in human plasma that declined with age. Half a century of dermatology work has followed.
The strongest evidence is topical. Multiple placebo-controlled trials of GHK-Cu creams and serums at concentrations around 3 percent have shown improved wound healing, reduced fine lines, increased skin thickness, and improved elasticity. Meta-analyses of dermatology trials rank GHK-Cu alongside retinoids among the better-supported topical anti-aging actives. Mechanistically, GHK-Cu upregulates collagen and glycosaminoglycan synthesis in fibroblasts, promotes angiogenesis, and modulates matrix metalloproteinase activity.
The systemic story is much thinner. Injectable GHK-Cu is used in some biohacker protocols at 1 to 2 mg subcutaneous daily for wound healing, post-surgical recovery, or generalized anti-aging effects. Preclinical work suggests systemic GHK-Cu upregulates genes involved in tissue repair and reduces markers of inflammation. No completed human RCT of injectable GHK-Cu for longevity endpoints has reached the literature.
A 2010 paper by Pickart and colleagues reported that GHK-Cu treatment of human fibroblasts reset gene expression toward younger profiles across roughly 4000 genes. This is often cited in the biohacker community as evidence for a systemic rejuvenation effect. The result has not been replicated in a human tissue context in vivo.
Copper toxicity is a real consideration with chronic systemic dosing. GHK-Cu delivers copper to tissues, and Wilson's disease patients or anyone with copper metabolism issues should not use it systemically without physician monitoring of copper and ceruloplasmin.
Our position: Topical GHK-Cu sits at Tier 2 for skin repair (multiple placebo-controlled trials, meta-analyses). Systemic injectable GHK-Cu sits at Tier 5 for longevity endpoints (mechanistic and cell-culture data only, no completed human RCT).
GHK-Cu is the best-studied cosmetic peptide on this list, with real controlled skin trials for wrinkles and wound healing, but it was pulled from FDA's Category 1 list in April 2026 after its nomination was withdrawn.
Verified 2026-08-06. We update this section as PCAC decisions, ClinicalTrials.gov entries, and new peer-reviewed studies land.
FDA / PCAC (July 2026)
Not reviewed at July 2026 PCAC meeting. GHK-Cu was removed from FDA's Category 1 bulk substances list on April 15, 2026 after its nomination was withdrawn, an administrative action separate from the seven-peptide PCAC vote (https://www.jdsupra.com/legalnews/fda-announces-removal-of-12-peptides-3731131/).
US status
Legal and widely sold as a cosmetic ingredient in topical skincare products (not a drug claim); injectable GHK-Cu for therapeutic use is not FDA approved and was removed from Category 1 compounding eligibility in April 2026.
EU status
Permitted as a cosmetic ingredient in topical formulations under EU cosmetics regulation; not authorised as an injectable therapeutic in the EU as of 2026.
Best-supported claim
GHK-Cu has the most human data of any peptide reviewed here for a cosmetic indication: a widely cited 2008 review describes controlled studies on aged skin showing GHK-Cu tightens skin and improves elasticity, firmness, and photodamage appearance, and states it stimulates wound healing "in numerous models and in humans" (https://pubmed.ncbi.nlm.nih.gov/18644225/). A new phase 2 randomized, vehicle-controlled, split-wound trial in 60 healthy adults is now testing whether topical GHK-Cu accelerates wound re-epithelialization versus vehicle gel using a paired-wound design that controls for individual variation (https://clinicaltrials.gov/study/NCT07437586).
Not supported by the evidence base
Injectable GHK-Cu is marketed by peptide vendors for systemic anti-aging, hair regrowth, and organ-protective effects extrapolated from topical skin-study data and rodent liver-protection experiments (https://pmc.ncbi.nlm.nih.gov/articles/PMC6073405/). The topical cosmetic evidence for skin firmness does not transfer to injectable systemic claims. GHK-Cu is also a core component of the unregulated "KLOW" combination protocol, sold with no safety data on the stacked combination and known copper-accumulation risk (https://newtropin.com/blog/kpv-gi-dermatological-inflammation-research).
Typical usage
Topical: 0.1% w/w gel or cream applied once or twice daily for cosmetic skin use, per the design of the ongoing wound-healing trial. Injectable/subcutaneous use in wellness protocols runs 1-2 mg daily or every other day in 4-6 week cycles, but this route has no completed controlled human efficacy trial.
Safety
Topical GHK-Cu has a long safety record as a cosmetic ingredient, but a Nature Scientific Reports biomarker study found certain copper compounds can cause measurable skin toxicity signals, underscoring that "copper peptide" is not automatically risk-free at all concentrations (https://www.nature.com/articles/srep37664). Injectable use carries unassessed systemic copper-load risk, especially when combined with other copper-containing peptides in stacks like KLOW. People with Wilson's disease or other copper-metabolism disorders should avoid GHK-Cu in any form. Local skin irritation, redness, and itching are the most common reported topical adverse effects.
Interactions worth flagging
- No formal systemic drug-interaction studies for injectable use
- Additive copper-load risk when combined with KPV in the unstudied KLOW protocol
- Theoretical interaction with penicillamine or other copper-chelating therapies
Three recent studies to know
-
Topical GHK-Cu Gel for Acute Skin Wound Healing (CuHeal)
Phase 2, randomized, double-blind, vehicle-controlled, split-wound trial testing whether topical GHK-Cu accelerates wound re-epithelialization; currently recruiting.
Read study → -
The human tri-peptide GHK and tissue remodeling
Review states GHK-Cu stimulates wound healing in numerous preclinical models and in humans, and improves skin elasticity, firmness, and photodamage in controlled aged-skin studies.
Read study → -
FDA Announces Removal of 12 Peptides from Category 2 and Category 1 Bulk Substance Lists
FDA removed GHK-Cu from the Category 1 bulk substances list on April 15, 2026 after its nomination was withdrawn.
Read study →
Further reading
Curated external sources for a deeper dive. External links open in a new tab.